Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (351-360 of 466) with videos related to

Pageof 47
Sort By:
The Lancet. Oncology|February 1, 2017
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trialAndrew D Zelenetz, Jacqueline C Barrientos, Jennifer R Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.
Blood|April 15, 2024
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trialMoritz Fürstenau, Adam Giza, Jonathan Weiss, et al.
Immunity|December 8, 2021
Interleukin-10 receptor signaling promotes the maintenance of a PD-1<sup>int</sup> TCF-1<sup>+</sup> CD8<sup>+</sup> T cell population that sustains anti-tumor immunityBola S Hanna, Laura Llaó-Cid, Murat Iskar, et al.
Nature Communications|October 23, 2023
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemiaOthman Al-Sawaf, Can Zhang, Hyun Yong Jin, et al.
Plos Genetics|April 18, 2013
Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kBAngela Garding, Nupur Bhattacharya, Rainer Claus, et al.
Leukemia|March 27, 2019
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemiaBilly Michael Chelliah Jebaraj, Eugen Tausch, Dan A Landau, et al.
Haematologica|February 29, 2020
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trialPaula Cramer, Julia V Tresckow, Sandra Robrecht, et al.
Blood|November 10, 2021
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemiaPetra Langerbeins, Can Zhang, Sandra Robrecht, et al.
Leukemia|July 1, 2020
COVID-19 among fit patients with CLL treated with venetoclax-based combinationsMoritz Fürstenau, Petra Langerbeins, Nisha De Silva, et al.
Pageof 47

Showing results (351-360 of 466) with videos related to

Sort By:
Pageof 47
The Lancet. Oncology|February 1, 2017
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trialAndrew D Zelenetz, Jacqueline C Barrientos, Jennifer R Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.
Blood|April 15, 2024
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trialMoritz Fürstenau, Adam Giza, Jonathan Weiss, et al.
Immunity|December 8, 2021
Interleukin-10 receptor signaling promotes the maintenance of a PD-1<sup>int</sup> TCF-1<sup>+</sup> CD8<sup>+</sup> T cell population that sustains anti-tumor immunityBola S Hanna, Laura Llaó-Cid, Murat Iskar, et al.
Nature Communications|October 23, 2023
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemiaOthman Al-Sawaf, Can Zhang, Hyun Yong Jin, et al.
Plos Genetics|April 18, 2013
Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kBAngela Garding, Nupur Bhattacharya, Rainer Claus, et al.
Leukemia|March 27, 2019
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemiaBilly Michael Chelliah Jebaraj, Eugen Tausch, Dan A Landau, et al.
Haematologica|February 29, 2020
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trialPaula Cramer, Julia V Tresckow, Sandra Robrecht, et al.
Blood|November 10, 2021
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemiaPetra Langerbeins, Can Zhang, Sandra Robrecht, et al.
Leukemia|July 1, 2020
COVID-19 among fit patients with CLL treated with venetoclax-based combinationsMoritz Fürstenau, Petra Langerbeins, Nisha De Silva, et al.
Pageof 47